Potomac Fund Management’s Boston Scientific BSX Stock Holding History

Potomac Fund Management’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,317	Closed	-$221K	–	108
2025 Q4	$221K	Buy	+2,317	New	+$227K	0.01%	105

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Potomac Fund Management's BSX Position: Q1 2026 in Review

Potomac Fund Management sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 2,317 shares — an estimated $221K sold.

Potomac Fund Management first reported a position in BSX in Q4 2025 and held it in 1 quarter. The position peaked at $221K in Q4 2025. 1,666 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Potomac Fund Management reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Potomac Fund Management sold 2,317 Boston Scientific shares in Q1 2026, an estimated $221K.
Potomac Fund Management first reported a position in Boston Scientific in Q4 2025 and held it in 1 quarter.
Potomac Fund Management's Boston Scientific position peaked at $221K in Q4 2025.
1,666 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Potomac Fund Management's 13F filing for Q1 2026, filed 14 May 2026.